CN107074950A - 使用抗nkg2a抗体的治疗方案 - Google Patents

使用抗nkg2a抗体的治疗方案 Download PDF

Info

Publication number
CN107074950A
CN107074950A CN201580050103.1A CN201580050103A CN107074950A CN 107074950 A CN107074950 A CN 107074950A CN 201580050103 A CN201580050103 A CN 201580050103A CN 107074950 A CN107074950 A CN 107074950A
Authority
CN
China
Prior art keywords
antibody
nkg2a
optionally
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580050103.1A
Other languages
English (en)
Chinese (zh)
Inventor
帕斯卡莱·安德烈
马蒂厄·布莱里
卡里纳·帕蒂雷尔
卡洛琳·苏拉
尼古拉·沃特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN107074950A publication Critical patent/CN107074950A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201580050103.1A 2014-09-16 2015-09-15 使用抗nkg2a抗体的治疗方案 Pending CN107074950A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462050948P 2014-09-16 2014-09-16
US62/050,948 2014-09-16
US201462067642P 2014-10-23 2014-10-23
US62/067,642 2014-10-23
US201462083929P 2014-11-25 2014-11-25
US62/083,929 2014-11-25
US201462093124P 2014-12-17 2014-12-17
US201462093141P 2014-12-17 2014-12-17
US62/093,124 2014-12-17
US62/093,141 2014-12-17
PCT/EP2015/071073 WO2016041947A1 (en) 2014-09-16 2015-09-15 Treatment regimens using anti-nkg2a antibodies

Publications (1)

Publication Number Publication Date
CN107074950A true CN107074950A (zh) 2017-08-18

Family

ID=54105801

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580050103.1A Pending CN107074950A (zh) 2014-09-16 2015-09-15 使用抗nkg2a抗体的治疗方案

Country Status (13)

Country Link
US (4) US10676523B2 (cg-RX-API-DMAC10.html)
EP (1) EP3193929B1 (cg-RX-API-DMAC10.html)
JP (4) JP2017538660A (cg-RX-API-DMAC10.html)
KR (2) KR20240141862A (cg-RX-API-DMAC10.html)
CN (1) CN107074950A (cg-RX-API-DMAC10.html)
AU (3) AU2015316993B2 (cg-RX-API-DMAC10.html)
DK (1) DK3193929T3 (cg-RX-API-DMAC10.html)
ES (1) ES2742456T3 (cg-RX-API-DMAC10.html)
HU (1) HUE044704T2 (cg-RX-API-DMAC10.html)
IL (1) IL250672B (cg-RX-API-DMAC10.html)
PL (1) PL3193929T3 (cg-RX-API-DMAC10.html)
SG (2) SG11201701387SA (cg-RX-API-DMAC10.html)
WO (1) WO2016041947A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020094071A1 (zh) * 2018-11-07 2020-05-14 上海怀越生物科技有限公司 Nkg2a抗体及其制备方法和应用
CN112004828A (zh) * 2018-03-13 2020-11-27 依奈特制药公司 头颈癌的治疗
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
KR20250007689A (ko) 2014-09-16 2025-01-14 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
SMT202100280T1 (it) 2016-01-21 2021-07-12 Innate Pharma Neutralizzazione delle vie inibitorie nei linfociti
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018073363A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
WO2019011852A1 (en) * 2017-07-10 2019-01-17 Innate Pharma POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
WO2019219658A1 (en) 2018-05-15 2019-11-21 Medimmune Limited Treatment of cancer
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
WO2020205440A1 (en) * 2019-03-29 2020-10-08 Dren Bio, Inc. Methods of reducing large granular lymphocyte and natural killer cell levels
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル-マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021090146A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Combination therapy for treating cancer
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
JP2023525049A (ja) * 2020-05-08 2023-06-14 シアトル・チルドレンズ・ホスピタル・ドゥーイング/ビジネス/アズ・シアトル・チルドレンズ・リサーチ・インスティテュート ナチュラルキラー細胞を標的とするキメラ抗原受容体(car)
CN116234568A (zh) 2020-07-07 2023-06-06 生物技术公司 用于hpv阳性癌症的治疗性rna
CN116194125A (zh) * 2020-08-07 2023-05-30 克莱格医学有限公司 工程化改造的细胞以及工程化改造细胞的方法
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
EP4221752A4 (en) 2020-09-30 2024-12-04 Dren Bio, Inc. ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性rna
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用
CA3222040A1 (en) * 2021-06-01 2022-12-08 Les Laboratoires Servier Anti-nkg2a antibodies and compositions
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Cldn18.2及びcd3に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
WO2024150017A1 (en) 2023-01-13 2024-07-18 Akrivia Biomedics Limited Method of profiling diseases
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
GB202417285D0 (en) 2024-11-25 2025-01-08 Univ Oxford Innovation Ltd Expanded t cell population
GB202418460D0 (en) 2024-12-16 2025-01-29 Univ Oxford Innovation Ltd Multivalent binding proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107269A (zh) * 2004-12-28 2008-01-16 依奈特制药公司 抗nkg2a的单克隆抗体
CN101484471A (zh) * 2006-06-30 2009-07-15 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
CN103635487A (zh) * 2011-06-17 2014-03-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
US20110033389A1 (en) 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
RU2017105425A (ru) 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
KR20250007689A (ko) 2014-09-16 2025-01-14 이나뜨 파르마 에스.에이. 림프구에서의 억제 경로의 중화
EP3209687A1 (en) * 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
SMT202100280T1 (it) 2016-01-21 2021-07-12 Innate Pharma Neutralizzazione delle vie inibitorie nei linfociti
TWI924623B (zh) 2018-03-13 2026-05-11 法商天賜製藥公司 頭頸癌之治療
WO2019219658A1 (en) 2018-05-15 2019-11-21 Medimmune Limited Treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107269A (zh) * 2004-12-28 2008-01-16 依奈特制药公司 抗nkg2a的单克隆抗体
CN101484471A (zh) * 2006-06-30 2009-07-15 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
CN103635487A (zh) * 2011-06-17 2014-03-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INNATE PHARMA: ""R&D update"", 《HTTP://INNATE-PHARMA.COM/SITES/DEFAULT/FILES/140410_RD_DAY_FINAL_0.PDF》 *
PETER LLOYD: "Challenges in early clinical development of biologics", 《HTTP://WWW.PHARMA.BE/ASSETS/FILES/2309/2309_129520955506916441.PDF》 *
徐仁宝等: "《受体的基础与临床》", 29 February 1992, 上海科学技术出版社 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004828A (zh) * 2018-03-13 2020-11-27 依奈特制药公司 头颈癌的治疗
WO2020094071A1 (zh) * 2018-11-07 2020-05-14 上海怀越生物科技有限公司 Nkg2a抗体及其制备方法和应用
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用

Also Published As

Publication number Publication date
WO2016041947A1 (en) 2016-03-24
AU2015316993A1 (en) 2017-03-16
JP2017538660A (ja) 2017-12-28
US12037392B2 (en) 2024-07-16
SG10202007781TA (en) 2020-09-29
JP7580506B2 (ja) 2024-11-11
IL250672B (en) 2020-10-29
CA2959463A1 (en) 2016-03-24
US10676523B2 (en) 2020-06-09
ES2742456T3 (es) 2020-02-14
AU2021203744A1 (en) 2021-07-01
AU2025205563A1 (en) 2025-08-07
IL250672A0 (en) 2017-04-30
US20240368281A1 (en) 2024-11-07
US20170298131A1 (en) 2017-10-19
JP2025016606A (ja) 2025-02-04
PL3193929T3 (pl) 2019-12-31
SG11201701387SA (en) 2017-03-30
EP3193929B1 (en) 2019-06-12
KR20170068458A (ko) 2017-06-19
AU2015316993B2 (en) 2021-03-18
EP3193929A1 (en) 2017-07-26
US20210238285A1 (en) 2021-08-05
AU2021203744B2 (en) 2025-04-24
DK3193929T3 (da) 2019-08-19
JP2021008487A (ja) 2021-01-28
HUE044704T2 (hu) 2019-11-28
JP2023055871A (ja) 2023-04-18
KR20240141862A (ko) 2024-09-27
US20200299383A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
JP7580506B2 (ja) 抗nkg2a抗体を使用した治療計画
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
JP7531667B2 (ja) リンパ球における阻害経路の中和
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes
HK40058058A (en) Neutralization of inhibitory pathways in lymphocytes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818